Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure

The plasma of COVID-19 patients induces pulmonary microvascular barrier failure, which increases with disease severity. Here, a screening platform to test for plasma mediators and the therapeutic potential of barrier stabilising compounds is reported. https://bit.ly/3k4C0tB

Detalles Bibliográficos
Autores principales: Michalick, Laura, Weidenfeld, Sarah, Grimmer, Benjamin, Fatykhova, Diana, Solymosi, Philip Daniel, Behrens, Felix, Dohmen, Melanie, Brack, Markus C., Schulz, Sabrina, Thomasch, Elisa, Simmons, Szandor, Müller-Redetzky, Holger, Suttorp, Norbert, Kurth, Florian, Neudecker, Jens, Toennies, Mario, Bauer, Torsten T., Eggeling, Stephan, Corman, Victor Max, Hocke, Andreas C., Witzenrath, Martin, Hippenstiel, Stefan, Kuebler, Wolfgang M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7651836/
https://www.ncbi.nlm.nih.gov/pubmed/33154030
http://dx.doi.org/10.1183/13993003.02384-2020
Descripción
Sumario:The plasma of COVID-19 patients induces pulmonary microvascular barrier failure, which increases with disease severity. Here, a screening platform to test for plasma mediators and the therapeutic potential of barrier stabilising compounds is reported. https://bit.ly/3k4C0tB

Ejemplares similares